Gene targets with therapeutic potential in hepatocellular carcinoma

doi:10.4251/wjgo.v16.i12.4543

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 16, Issue 12

This Article

Academic Content and Language Evaluation of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (571)

All Articles published online

The chart showing PDF series, HTML series.

Item

Count

PDF

HTML

378

Sum=400

Publishing Process of This Article

The chart showing Browse series, Download series.

Item

Count

Browse

Download

Sum=136

Dec 15, 2024 (publication date) through Jan 26, 2025

Times Cited of This Article

Times Cited (0)

Journal Information of This Article

Publication Name

World Journal of Gastrointestinal Oncology

ISSN

1948-5204

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Editorial

World J Gastrointest Oncol. Dec 15, 2024; 16(12): 4543-4547
Published online Dec 15, 2024. doi: 10.4251/wjgo.v16.i12.4543

Gene targets with therapeutic potential in hepatocellular carcinoma

Syifaus Shodry, Yuliono Trika Nur Hasan, Iwal Reza Ahdi, Zulvikar Syambani Ulhaq

Syifaus Shodry, Yuliono Trika Nur Hasan, Iwal Reza Ahdi, Faculty of Medicine and Health Sciences, Maulana Ibrahim Islamic State University of Malang, Malang 65144, Jawa Timur, Indonesia

Zulvikar Syambani Ulhaq, Research Center for Preclinical and Clinical Medicine, National Research and Innovation Agency Republic of Indonesia, Cibinong 16911, Indonesia

Author contributions: Shodry S wrote the original manuscript; Hasan YTN and Ahdi IR supervised the project; Ulhaq ZS conceived the study, wrote the original draft and revised the manuscript, and supervised the study; Ulhaq ZS was the main contributor to this manuscript.

Conflict-of-interest statement: The authors have no conflicts of interest to declare.

Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/

Corresponding author: Zulvikar Syambani Ulhaq, MD, PhD, Research Scientist, Research Center for Preclinical and Clinical Medicine, National Research and Innovation Agency Republic of Indonesia, Cibinong Science Center, Jl. Raya Jakarta-Bogor, Cibinong 16911, Indonesia. zulvikar.syambani.ulhaq@brin.go.id

Received: June 27, 2024
Revised: August 3, 2024
Accepted: August 13, 2024
Published online: December 15, 2024
Processing time: 138 Days and 8.4 Hours

Core Tip

Core Tip: Hepatocellular carcinoma (HCC) is one of the leading causes of cancer-related deaths due to late diagnosis and high recurrence rates. Key biomarkers such as enhancer of zeste homolog 2 and fatty acid binding protein 5, along with other genetic biomarkers provide insights into HCC progression and potential therapeutic targets.